Literature DB >> 22092633

Pharmacodynamic monitoring of canine T-cell cytokine responses to oral cyclosporine.

T M Archer1, C L Fellman, J V Stokes, L M Pinchuk, K V Lunsford, S B Pruett, V C Langston, A J Mackin.   

Abstract

BACKGROUND: Pharmacodynamic assays measure the immunosuppressive effects of cyclosporine on T-cells and offer an alternative assessment of efficacy in individual patients.
OBJECTIVE: To assess the immunosuppressive effects of high and low dosage cyclosporine on canine T-cells and to develop a novel testing system for individualized dose adjustment. ANIMALS: Seven healthy female Walker hounds.
METHODS: Experimental study using a paired comparison design. Flow cytometry was used to measure T-cell expression of IL-2, IL-4, and IFN-γ. Cytokine expression 8 days after oral administration of high and low dosages of cyclosporine was compared to baseline and washout values, respectively. The high dosage was initially 10 mg/kg q12h and was then adjusted to attain established immunosuppressive trough blood drug concentrations (>600 ng/mL). The low dosage was 5 mg/kg q24h.
RESULTS: High dosage cyclosporine resulted in significant decreases in IL-2 and IFN-γ expression (P = .0156, P = .0156), but not IL-4 expression (P = .2188). Low dosage cyclosporine was associated with a significant decrease in IFN-γ expression (P = .0156), while IL-2 expression was not affected (P = .1094). CONCLUSIONS AND CLINICAL IMPORTANCE: T-cell function is suppressed at trough blood drug concentrations exceeding 600 ng/mL, and is at least partially suppressed in some dogs at low dosages. Direct evaluation of T-cell function could be an effective, more sensitive alternative to measuring blood drug concentrations for monitoring immunosuppressive therapy.
Copyright © 2011 by the American College of Veterinary Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22092633     DOI: 10.1111/j.1939-1676.2011.00797.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  19 in total

1.  In-vitro immunosuppression of canine T-lymphocyte-specific proliferation with dexamethasone, cyclosporine, and the active metabolites of azathioprine and leflunomide in a flow-cytometric assay.

Authors:  Laura A Nafe; John R Dodam; Carol R Reinero
Journal:  Can J Vet Res       Date:  2014-07       Impact factor: 1.310

2.  Calcitriol-mediated reduction in IFN-γ output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation.

Authors:  Paige M Kulling; Kristine C Olson; Thomas L Olson; Cait E Hamele; Kathryn N Carter; David J Feith; Thomas P Loughran
Journal:  J Steroid Biochem Mol Biol       Date:  2017-07-20       Impact factor: 4.292

3.  Pharmacodynamic assessment of ex-vivo canine T-lymphocyte proliferation: Responses to dexamethasone, cyclosporine, mycophenolic acid, and the active metabolite of leflunomide.

Authors:  Megan Grobman; Kaitlin A Bishop; Hansjorg Rindt; Laura A Nafe; Carol R Reinero
Journal:  Can J Vet Res       Date:  2019-10       Impact factor: 1.310

4.  Pharmacokinetic evaluation of oral dantrolene in the dog.

Authors:  J L Haraschak; V C Langston; R Wang; C Riggs; C Fellman; M K Ross; C Bulla; K Lunsford; A Mackin; T Archer
Journal:  J Vet Pharmacol Ther       Date:  2013-11-13       Impact factor: 1.786

5.  Analytical validation of a quantitative reverse transcriptase polymerase chain reaction assay for evaluation of T-cell targeted immunosuppressive therapy in the dog.

Authors:  C Riggs; T Archer; C Fellman; A S Figueiredo; J Follows; J Stokes; R Wills; A Mackin; C Bulla
Journal:  Vet Immunol Immunopathol       Date:  2013-12-15       Impact factor: 2.046

6.  Expressional time phase of leukocyte molecules induced by allogenic cardiac antigen and cyclosporin A in rats' in vitro model.

Authors:  Xiu-Fang Xu; Yi Xin; Ying Zhang; Yi-Min Huang; Yun Gu; Na Li; Wen-Bin Li; Yu-Jie Zhou; Zhao-Guang Zhang
Journal:  Int J Clin Exp Med       Date:  2013-05-22

7.  Effects of oral cyclosporine on canine T-cell expression of IL-2 and IFN-gamma across a 12-h dosing interval.

Authors:  C L Fellman; T M Archer; J V Stokes; R W Wills; K V Lunsford; A J Mackin
Journal:  J Vet Pharmacol Ther       Date:  2015-12-17       Impact factor: 1.786

8.  Cyclosporine reduces the spleen dimensions in rabbits.

Authors:  Luiz Ronaldo Alberti; Leonardo de Souza Vasconcellos; Andy Petroianu
Journal:  Acta Cir Bras       Date:  2021-05-07       Impact factor: 1.388

Review 9.  Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis.

Authors:  Tim Nuttall; Douglas Reece; Elizabeth Roberts
Journal:  Vet Rec       Date:  2014-03       Impact factor: 2.695

10.  Unsuccessful cyclosporine plus prednisolone therapy for autoimmune meningoencephalitis in three dogs.

Authors:  Dong-In Jung; Hee-Chun Lee; Jeongim Ha; Hae-Won Jung; Joon-Hyeok Jeon; Jong-Hyun Moon; Jae-Hoon Lee; Na-Hyun Kim; Jung-Hyang Sur; Byeong-Teck Kang; Kyu-Woan Cho
Journal:  J Vet Med Sci       Date:  2013-08-13       Impact factor: 1.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.